PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Share Price Deutsche Boerse AG
Equities
2E40
FR001400K4B1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.89 EUR | -9.79% |
|
-3.57% | -57.53% |
| Sales 2024 * | 1.05M 1.12M 89.01M | Sales 2025 * | 1.6M 1.71M 136M | Capitalization | 12.09M 12.95M 1.02B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 1M 1.07M 84.77M | EV / Sales 2024 * | 13.1 x |
| Net Debt 2024 * | 1.7M 1.82M 144M | Net Debt 2025 * | 15.25M 16.33M 1.29B | EV / Sales 2025 * | 17.1 x |
| P/E ratio 2024 * |
-1.09
x | P/E ratio 2025 * |
-2.19
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 day | -9.79% | ||
| 1 week | -3.57% | ||
| Current month | -35.38% | ||
| 1 month | -35.71% | ||
| 3 months | -34.38% | ||
| 6 months | -57.05% | ||
| Current year | -57.53% |
1 week
1.89
2.10
1 month
1.892.95
Current year
1.894.55
1 year
1.898.12
3 years
1.8978.00
5 years
1.89107.00
10 years
1.89294.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 22/06/23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 22/06/23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 22/06/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 22/06/23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 22/06/23 |
Gil Beyen
BRD | Director/Board Member | 62 | 22/06/23 |
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 1.89 | -9.79% |
| 27/06/24 | 2.095 | +1.70% |
| 26/06/24 | 2.06 | +3.52% |
| 25/06/24 | 1.99 | +1.02% |
| 24/06/24 | 1.97 | +0.51% |
Delayed Quote Deutsche Boerse AG, June 28, 2024 at 08:41 pm
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
24/09/2024
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.99
EUR
Average target price
5.1
EUR
Spread / Average Target
+156.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.20% | 121B | |
| +19.67% | 113B | |
| +18.95% | 26.02B | |
| -23.86% | 19.39B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B |
- Stock Market
- Equities
- PHXM Stock
- 2E40 Stock
